In this sub-investigation of the STAR SIGN study, we quantified mucosal IgG and IgA targeting the SARS-CoV-2 JN.1 variant receptor-binding domain (RBD) in immunocompromised patients with IBD before and after immunization with XBB.1.5 mRNA vaccines. Here, CD79A is linked to inflammatory bowel disease.